Glooko announced today that its platform now supports the Abbott FreeStyle Libre continuous glucose monitoring (CGM) in the U.S.
The integration further strengthens Glooko’s commitment to offering a comprehensive, all-in-one solution for managing diabetes. Palo Alto, California-based Glooko’s current platforms enable patients to share diabetes data with healthcare providers. That includes blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight.
Recent endeavors for Glooko include digital therapeutics and insulin delivery partnerships. Glooko also appointed a new CEO, Mike Alvarez, and raised $100 million last fall.
With the new integration, people with diabetes can seamlessly connect data from their FreeStyle Libre CGMs with other key health metrics. That includes insulin usage, exercise and diet, providing a unified view of their health. Providers can also access a more complete, consolidated picture of their patient’s diabetes management. This streamlines daily care and enhances clinical decision-making.
Glooko and Abbott offer this integration for individuals with type 1 and type 2 diabetes and healthcare systems across the U.S. through the former’s established electronic health record (EHR) integration solutions.
“Diabetes care is evolving rapidly, and Glooko is leading the way by providing a single, unified platform for managing all aspects of diabetes,” said Alvarez. “With this integration, Glooko continues to enhance its interoperability capabilities, providing healthcare systems with the data they need to make more informed decisions and improve patient outcomes.”
